Home › Compare › IGDFF vs ABBV
IGDFF yields 235.30% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 10
Combined, IGDFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IGDFF + ABBV for your $10,000?
IG Design Group plc designs, manufactures, and distributes celebrations, craft and creative play, stationery, gifting, and not for re-sale consumable products in the Americas, the United Kingdom, and internationally. It provides celebrations products, including greetings cards, gift wraps, Christmas crackers, gift bags, and partyware products, as well as gift accessories, such as tags, strings, ribbons, and bows; and gifting products comprise frames, albums, calendars and diaries, as well as food and non-food gifts. The company also offers ribbons and trims, sewing patterns, buttons, needlecrafts, and kids craft lines; stationery products, including pencils, pens, notebooks, pencil cases, clips, journals, etc. for use in education, commercial, and home settings; and bin liners, refuse sacks, food bags, and other collateral products, as well as paper twist handle bags. It serves retailers, other manufacturers and wholesalers of greetings products, service merchandisers, and trading companies. The company was formerly known as International Greetings plc and changed its name to IG Design Group plc in June 2016. IG Design Group plc was incorporated in 1978 and is based in Newport Pagnell, the United Kingdom.
Full IGDFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.